<DOC>
	<DOCNO>NCT01336465</DOCNO>
	<brief_summary>This Phase II study randomize , double-blind , placebo-controlled multicenter study evaluate efficacy safety rhuMAb Beta7 patient moderate severe ulcerative colitis .</brief_summary>
	<brief_title>Evaluate Efficacy Safety rhuMAb Beta7 Patients With Moderate Severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Diagnosis moderate severe ulcerative colitis outpatient Disease duration time screen &gt; /= 12 week Extensive colonic resection subtotal total colectomy Presence ileostomy colostomy Moderate severe anemia A history evidence colonic mucosal dysplasia Pregnant lactating Significant uncontrolled comorbidity , neurological , cardiac , pulmonary , renal , hepatic , endocrine , gastrointestinal ( GI ) disorder Significant screen ECG abnormality , include evidence acute myocardial infarction , complete leave bundle branch block , seconddegree heart block , complete heart block Poorly control diabetes Impaired renal function Impaired hepatic function absence diagnosis primary sclerosing cholangitis Positive test antibody indicate active prior infection HIV hepatitis B ( HBV ) C ( HCV ) Positive screen test latent mycobacterium tuberculosis ( TB ) infection Demyelinating disease Received investigational treatment within 12 week prior initiation study treatment Previous exposure rhuMAb Beta7</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>